Navigation Links
Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Date:7/22/2009

CHICAGO, July 22 /PRNewswire-FirstCall/ -- Research presented at the American Association for Clinical Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant patients with the Urine NGAL assay on Abbott's ARCHITECT immunoassay analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to prevent possible irreversible kidney damage.

In a scientific poster presented at AACC today by researchers at the University of Toronto, eleven heart transplant patients were treated with anti-rejection drug combinations and monitored with the Urine NGAL assay within twelve hours of administration. The study concluded that Urine NGAL monitoring may be able to assist in the detection of chronic cyclosporine-induced toxicity in the kidneys following heart transplant procedures.

Abbott is currently developing an assay to measure NGAL (neutrophil gelatinase-associated lipocalin) concentrations in urine for use on the company's flagship automated laboratory instrument, the ARCHITECT system. Abbott has rights to commercialize Urine NGAL for renal diagnostic applications and is expected to introduce the product in Europe in late 2009. The assay is not available in the United States. NGAL is a small, robust protein produced by the kidney tubules and appears in urine just two-to-four hours following acute kidney injury (AKI), up to 46 hours sooner than current test methods.

"Nephrologists and cardiologists are excited about the potential of Urine NGAL to detect the potential for kidney failure following cardio-thoracic surgeries," said Sudarshan Hebbar, M.D., medical director, Abbott Diagnostics.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, referen
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
2. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
3. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
4. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
5. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
6. Retrospective Analysis of Phase 3 Data Suggest Wyeths Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
7. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
8. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393
9. U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia
10. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
11. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...re-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),abiop...alizingnovelpainmanagementtherapies,announcedtoday...er,isscheduledtopresentatthe21stAnnualPiperJaffray...NewYorkPalaceHotelinNewYork,NewYork. ,, Mr.DiTo...eavailabletorespondtoquestionsduringthepresentatio...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/-HamiltonThorneLtd.(TSX...rofadvancedlasersystemsandinstrumentsforthestemcel...erationalandfinancialresultsforthethirdquarterende...as$1.46millioncomparedwith$1.43millioninQ32008,-Gr...ntinQ3,2008,-Netlossreducedto$148,000comparedto$28...
(Date:11/24/2009)...cts Customers with Partners Validated to Process a...ucts , Ottawa, ON (PRWEB)...vider of products for biological sample collection...ts new global partner program. The program offers ... community and is designed to help partners scale ...
(Date:11/23/2009)... communication, computation and more powerful ways...se quantum states as carriers of information is an...ave shown, mathematically, how to gently tease out...eping the information intact. Their work is report...s and highlighted with a Viewpoint in Physics (...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...VIV, Israel, March 25 BSP Ltd.,( http://www.bsp.c...lops and,markets systems for non-invasive diagnosi...e launching their HyperQ(TM) Stress System in the ...o, IL., The HyperQ(TM) is cutting-edge technology...offering highly reliable, low-cost and risk free,c...
...TOWN, Mass., March 25 Boston Biomedical Research,...once again given a Baa3,bond rating with a stable ...e Institute,s financial stability in an era of dec...onomy that have left some similar,organizations st...firmation,of our financial health," says BBRI Dire...
...OD CITY, Calif., March 25 Codexis, Inc., today,an...he newly-created,position of Vice President, Bioin...is from DuPont, where he was Venture Manager, Biof...t and CEO., "Codexis targets major global energy ...an make a significant impact," said Alan Shaw, Ph....
Other Biology Technology:World Debut for BSP's HyperQ Stress System: 57th Annual American College of Cardiology Meeting 2008 2Boston Biomedical Research Institute Maintains Baa3 Rating from Moody's 2Codexis Names David Anton VP Bioindustrials R&D 2
(Date:11/23/2009)...ONTO, November 23, 2009 - The time of day matters ... a new paper produced by a research team led by Pr...arborough,s vice-principal for research and collea... at the St. George campus. , Capitalizing on t...lar tree, the research team examined how poplar tr...
(Date:11/23/2009)...E, Calif. -- More than 160 participants gathered t... Keck FUTURES INITIATIVE conference. This year,s t...ists, engineers, and medical researchers to explor...urrounding the emerging field of synthetic biology...ology at Princeton University and this year,s conf...
(Date:11/23/2009)...MPAIGN, Ill. A new study provides "incontrovertib...oba on the island of Sumatra about 73,000 years ag...es from the epicenter, researchers report. , The... of ash into the atmosphere, leaving a crater (now...lometers long and 35 kilometers wide. Ash from the...
Breaking Biology News(10 mins):Time of day matters to thirsty trees, U of T researcher discovers 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Athera Receives Allowance of Two Key Patents 14468 1Athera Receives Allowance of Two Key Patents 14468 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 1Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 3Solos Endoscopy Inc s FDA Approved MammoView 28TM 29 Product Line to Obtain CE Mark 5465 1Solos Endoscopy Inc s FDA Approved MammoView 28TM 29 Product Line to Obtain CE Mark 5465 2
...cking an adhesive protein secreted by mussels and ...ers at Northwestern University have designed a ver...fe into medical implants. , Currently the longevi...teria, cells and proteins in the body gradually ac...mising their performance and threatening patients ...
...al meeting of the United Nations Forum on Forests,...o protect the world,s forests or, some environment...tiations. , One member of the U.S. delegation to ...cy expert Matthew Auer, who remains guardedly opti... with one or more concrete outcomes, such as a fun...
... inflammation is linked to the development of cert...ammation during premalignancy are not well underst...ue of Cancer Cell identifies B lymphocytes as impo...chronic inflammation. The results suggest that dru...f innate immune cells toward premalignant tissue m...
Other Biology News:Innovative coating could give medical implants a longer life 2U.N. mulls the protection of Earth's forests 2B cells are required for development of epithelial cancer associated with chronic inflammation 2
...6850 Networked GC is an excellent choice for suppo...t of a standard dual-channel GC, this one-channel ... two GCs in the space of one. You get all the capa...lyses in an instrument that has the same proven pe...
... and compact GC-8A is Shimadzu's basic gas chromat...l and simple to use, the GC-8A supports a single d...n injection port(s), and analog output. Isothermal...ilable. The GC-8A is only 17.3 inches (43.9 cm) wi...
...mon's laboratory animal infusion kits reduce the t... while providing sterile equipment to reduce the r... need for one animal, including swivel, tubing, te...t to the exact lengths you specify, preassembled i...
HCT Plus from Bruker Daltonics
Biology Products: